Clinical Trials Logo

Pain, Cancer clinical trials

View clinical trials related to Pain, Cancer.

Filter by:

NCT ID: NCT04572776 Withdrawn - Pain, Intractable Clinical Trials

Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain

Start date: December 2020
Phase: Phase 3
Study type: Interventional

This is a Phase 3 study to assess the safety and efficacy of a single epidural administration of Resiniferatoxin versus standard of care for the treatment of intractable pain associated with cancer.

NCT ID: NCT04176575 Completed - Metastatic Cancer Clinical Trials

Balancing Method for Pain Related to Advanced Cancer

Start date: July 5, 2022
Phase: N/A
Study type: Interventional

Balancing Method for Pain Related to Advanced Cancer seeks to confirm the benefit of acupuncture for patients with pain related to advanced cancer.

NCT ID: NCT03727373 Completed - Pain, Acute Clinical Trials

Qualitative Study for Pain Measurement Using Innovative Health Technology

QualiPain
Start date: October 17, 2018
Phase:
Study type: Observational

The present study is a multicenter, explorative, qualitative study. The primary endpoint of this study is to evaluate to which extent the collection of data with regard to pain caused by illness or treatment can be optimized using health technology solutions. For this evaluation semi-structured qualitative interviews with 8-10 patients will be conducted. Secondary variables are the evaluation of the patients' pain experience and the general patients' willingness to collect data with regard to pain by using technological devices themselves or with support of healthcare professionals.

NCT ID: NCT03297723 Recruiting - Pain Cancer Clinical Trials

Effectiveness of a Patient Therapeutic Education Program in Improving Pain Management

EFFADOL-K
Start date: December 18, 2017
Phase:
Study type: Observational

Pain is one of the most feared and burdensome symptoms experienced by cancer patients. Its prevalence has been estimated by INCa1 in 2012 at 48% in patients undergoing cancer treatment, and unrelieved pain is directly associated with significantly reduced quality of life (QoL)2. A large part of cancer pain undertreatment can be attributed to patient-related barriers. Patient barriers are multifactorial and often result from a lack of knowledge about cancer pain and its self-management. They mainly consist of misconceptions about opioids and their side effects, nonadherence, and reluctance to alert health care providers to unrelieved pain. Patient education enables people with chronic disease to manage their illness, and has been considered in the field of cancer research as an important strategy to achieve optimal pain control. In Basse-Normandie french region, the "Health Regional Plan, pain aspect" has identified the theme " pain education program " as a priority. The main endpoint is the decrease of pain interference with daily life (using the Brief Pain Inventory). The experimental group, consisting of cancer pain patients, will benefit from the education program by previously trained health care providers. It will be compared with the control group, consisting with patients whose pain will be conventionally managed before the professional training in therapeutic education.

NCT ID: NCT01060124 Completed - Pain; Cancer Clinical Trials

An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Cancer Participants With Inadequately Controlled Pain by Non-Narcotic Analgesics

Start date: April 2007
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Transdermal Therapeutic System (TTS)-fentanyl D-Trans (transdermal patch containing a drug that is put on the skin so the drug will enter the body through the skin) treatment in cancer participants of Korea with inadequately controlled pain by non-narcotic analgesics (drug used to control pain) and participant's satisfaction.

NCT ID: NCT00684632 Completed - Pain, Cancer Clinical Trials

A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients

Start date: March 2008
Phase: Phase 3
Study type: Interventional

This study is designed to determine whether KW-2246 is superior to placebo and not inferior to immediate-release morphine for the relief of breakthrough pain in cancer patients.

NCT ID: NCT00683995 Completed - Pain, Cancer Clinical Trials

A Phase III Clinical Study of KW-2246

Start date: March 2008
Phase: Phase 3
Study type: Interventional

This study is designed to assess the safety and efficacy of long-term KW-2246 treatment as rescue medication for breakthrough pain.